The concurrent upregulation of TOP2A and EZH2 predicts a worse prognosis in patients with HCC, suggesting a therapeutic strategy for HCC that targets EZH2 to induce cellular senescence and then destroy senescent cells. This evidence concerns the gene TOP2A and hepatocellular carcinoma.